Framework Journal · one stock, one dated entry

Recorded 2026-05-22 · Permanent

Quince Therapeutics, Inc. QNCX

Outside both standards

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

The label
Markup

read at $1.01

Quince Therapeutics, Inc. holds its Markup at $1.01.

PHINPOOPSC
  • PHPhase · the trend structure carries the Markup label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · does not pass the values gate
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2026-05-22
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 12 days
Price$1.01
Valuation0.00 trailing · -0.92 forward price to earnings
Values screenFAIL
BetaN/A

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Forward P/E-0.9x
Trailing P/E0.0x
Revenue growth0.0%
revenue is shrinking
Profit margin0.0%
currently unprofitable
Return on equity-192.9%
not currently earning a positive return on equity
Debt to equity0.02
minimal debt — a conservative balance sheet
Market cap$21M

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & how to trade · wherever in the world you are

QNCX trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The trader read · the latest dated commentary

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 92%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (1 analysts) rates it none. Entered 2026-07-18 · Markdown

The dated journal · newest first, never edited

2026-07-18 Markdown $1.01 +0.0% Entry 3

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 92%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (1 analysts) rates it none.

2026-07-03 Markdown $1.01 +0.0% Entry 2

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.

2026-07-02 Markdown $1.01 Entry 1

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

The insider ledger · Form 4 filings, as filed

Most recent filings · QNCX
DateInsiderTitleTypeSharesValue
2025-12-26 LUCA BENATTI Director 50,000 $173,500
2025-12-10 THYE DIRK Chief Executive Officer 739,885 ·
2025-12-05 HANNAH BRENDAN Chief Operating Officer 27,551 $25,012
2025-06-18 RYAN CHARLES S President 7,548 $9,058
2025-06-18 THYE DIRK Chief Executive Officer 150,944 $181,133
2025-06-18 HANNAH BRENDAN Chief Operating Officer 37,736 $45,283
2024-08-30 THYE DIRK Chief Executive Officer 154,500 $107,375
2024-08-21 HANNAH BRENDAN Chief Operating Officer 38,924 $24,166
2024-08-20 RYAN CHARLES S President 48,387 $31,452
2024-06-04 HANNAH BRENDAN Chief Operating Officer 56,061 $30,834

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $1.24 -25.8% · $742 -25.8%
2 months $1.36 -32.4% · $677 -32.4%
3 months $1.07 -14.0% · $860 -14.0%
6 months $44.00 -97.9% · $21 -97.9%
1 year $12.00 -92.3% · $77 -92.3%
2 years $7.60 -87.9% · $121 -87.9%
3 years $15.80 -94.2% · $58 -94.2%
5 years $486.90 -99.8% · $2 -99.8%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever QNCX does next, these words stay.

Quince Therapeutics, Inc. · QNCX · Markup · $1.01
Recorded 2026-05-22 · before the outcome · scored mechanically

Get our weekly market brief free.